APO Research
Talk to an analyst

APO RESEARCH · REPORT

Malaria Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Malaria Vaccines Market Analysis and Forecast 2026-2032

22 December 2025216 pages

Choose your research edition.

Industry ResearchMalaria Vaccines Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Malaria Vaccines Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Malaria Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Malaria Vaccines Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Malaria Vaccines Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global Malaria Vaccines market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Malaria Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Malaria Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Malaria Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Malaria Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Malaria Vaccines include Sanofi, Novartis AG, Mylan N.V., Pfizer Inc, GlaxoSmithKline Plc, Zydus Cadila, VLP Therapeutics, Taj Pharmaceuticals Limited and Sun Pharmaceutical Industries Ltd, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Malaria Vaccines, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Malaria Vaccines, also provides the revenue of main regions and countries. Of the upcoming market potential for Malaria Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Malaria Vaccines revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Malaria Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Malaria Vaccines revenue, projected growth trends, production technology, application and end-user industry.

Malaria Vaccines Segment by Company

Sanofi

Novartis AG

Mylan N.V.

Pfizer Inc

GlaxoSmithKline Plc

Zydus Cadila

VLP Therapeutics

Taj Pharmaceuticals Limited

Sun Pharmaceutical Industries Ltd

Sumaya Biotech

Strides Pharma Science Limited

Sanaria Inc

OSIVAX

Nobelpharma Co

Lupin

Ipca Laboratories Ltd

Hikma Pharmaceuticals PLC

GeoVax

GenVec

Cipla Inc

CellFree Sciences

Bliss GVS Pharma Ltd

Amneal Pharmaceuticals LLC

AJANTA PHARMA

AdvaCare Pharma

Actiza Pharmaceutical Private Limited

Malaria Vaccines Segment by Type

Erythrocytic Vaccine

Pre-Erythrocytic Vaccine

Multi-antigen Vaccine

Malaria Vaccines Segment by Application

Clinics

Hospitals

Community Centers

Malaria Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Malaria Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Malaria Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Malaria Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Malaria Vaccines in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Malaria Vaccines company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Malaria Vaccines revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Malaria Vaccines Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Erythrocytic Vaccine Major Player Table 3. Pre-Erythrocytic Vaccine Major Player Table 4. Multi-antigen Vaccine Major Player Table 5. Global Malaria Vaccines Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Clinics Major Player Table 7. Hospitals Major Player Table 8. Community Centers Major Player Table 9. Malaria Vaccines Industry Trends Table 10. Malaria Vaccines Industry Drivers Table 11. Malaria Vaccines Industry Opportunities and Challenges Table 12. Malaria Vaccines Industry Restraints Table 13. Global Malaria Vaccines Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Malaria Vaccines Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Malaria Vaccines Market Share by Region (2021-2026) Table 16. Global Malaria Vaccines Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Malaria Vaccines Market Share by Region (2027-2032) Table 18. Global Malaria Vaccines Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Malaria Vaccines Revenue Market Share by Players (2021-2026) Table 20. Global Malaria Vaccines Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Malaria Vaccines Key Players Headquarters & Area Served Table 22. Global Malaria Vaccines Players, Product Type & Application Table 23. Global Malaria Vaccines Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Malaria Vaccines by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Malaria Vaccines Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Malaria Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Malaria Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Malaria Vaccines Revenue Market Share by Type (2021-2026) Table 30. Global Malaria Vaccines Revenue Market Share by Type (2027-2032) Table 31. Global Malaria Vaccines Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Malaria Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Malaria Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Malaria Vaccines Revenue Market Share by Application (2021-2026) Table 35. Global Malaria Vaccines Revenue Market Share by Application (2027-2032) Table 36. Sanofi Company Information Table 37. Sanofi Business Overview Table 38. Sanofi Malaria Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Sanofi Malaria Vaccines Product Portfolio Table 40. Sanofi Recent Development Table 41. Novartis AG Company Information Table 42. Novartis AG Business Overview Table 43. Novartis AG Malaria Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Novartis AG Malaria Vaccines Product Portfolio Table 45. Novartis AG Recent Development Table 46. Mylan N.V. Company Information Table 47. Mylan N.V. Business Overview Table 48. Mylan N.V. Malaria Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Mylan N.V. Malaria Vaccines Product Portfolio Table 50. Mylan N.V. Recent Development Table 51. Pfizer Inc Company Information Table 52. Pfizer Inc Business Overview Table 53. Pfizer Inc Malaria Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Pfizer Inc Malaria Vaccines Product Portfolio Table 55. Pfizer Inc Recent Development Table 56. GlaxoSmithKline Plc Company Information Table 57. GlaxoSmithKline Plc Business Overview Table 58. GlaxoSmithKline Plc Malaria Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. GlaxoSmithKline Plc Malaria Vaccines Product Portfolio Table 60. GlaxoSmithKline Plc Recent Development Table 61. Zydus Cadila Company Information Table 62. Zydus Cadila Business Overview Table 63. Zydus Cadila Malaria Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Zydus Cadila Malaria Vaccines Product Portfolio Table 65. Zydus Cadila Recent Development Table 66. VLP Therapeutics Company Information Table 67. VLP Therapeutics Business Overview Table 68. VLP Therapeutics Malaria Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. VLP Therapeutics Malaria Vaccines Product Portfolio Table 70. VLP Therapeutics Recent Development Table 71. Taj Pharmaceuticals Limited Company Information Table 72. Taj Pharmaceuticals Limited Business Overview Table 73. Taj Pharmaceuticals Limited Malaria Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Taj Pharmaceuticals Limited Malaria Vaccines Product Portfolio Table 75. Taj Pharmaceuticals Limited Recent Development Table 76. Sun Pharmaceutical Industries Ltd Company Information Table 77. Sun Pharmaceutical Industries Ltd Business Overview Table 78. Sun Pharmaceutical Industries Ltd Malaria Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Sun Pharmaceutical Industries Ltd Malaria Vaccines Product Portfolio Table 80. Sun Pharmaceutical Industries Ltd Recent Development Table 81. Sumaya Biotech Company Information Table 82. Sumaya Biotech Business Overview Table 83. Sumaya Biotech Malaria Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Sumaya Biotech Malaria Vaccines Product Portfolio Table 85. Sumaya Biotech Recent Development Table 86. Strides Pharma Science Limited Company Information Table 87. Strides Pharma Science Limited Business Overview Table 88. Strides Pharma Science Limited Malaria Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Strides Pharma Science Limited Malaria Vaccines Product Portfolio Table 90. Strides Pharma Science Limited Recent Development Table 91. Sanaria Inc Company Information Table 92. Sanaria Inc Business Overview Table 93. Sanaria Inc Malaria Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Sanaria Inc Malaria Vaccines Product Portfolio Table 95. Sanaria Inc Recent Development Table 96. OSIVAX Company Information Table 97. OSIVAX Business Overview Table 98. OSIVAX Malaria Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. OSIVAX Malaria Vaccines Product Portfolio Table 100. OSIVAX Recent Development Table 101. Nobelpharma Co Company Information Table 102. Nobelpharma Co Business Overview Table 103. Nobelpharma Co Malaria Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. Nobelpharma Co Malaria Vaccines Product Portfolio Table 105. Nobelpharma Co Recent Development Table 106. Lupin Company Information Table 107. Lupin Business Overview Table 108. Lupin Malaria Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. Lupin Malaria Vaccines Product Portfolio Table 110. Lupin Recent Development Table 111. Ipca Laboratories Ltd Company Information Table 112. Ipca Laboratories Ltd Business Overview Table 113. Ipca Laboratories Ltd Malaria Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 114. Ipca Laboratories Ltd Malaria Vaccines Product Portfolio Table 115. Ipca Laboratories Ltd Recent Development Table 116. Hikma Pharmaceuticals PLC Company Information Table 117. Hikma Pharmaceuticals PLC Business Overview Table 118. Hikma Pharmaceuticals PLC Malaria Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 119. Hikma Pharmaceuticals PLC Malaria Vaccines Product Portfolio Table 120. Hikma Pharmaceuticals PLC Recent Development Table 121. GeoVax Company Information Table 122. GeoVax Business Overview Table 123. GeoVax Malaria Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 124. GeoVax Malaria Vaccines Product Portfolio Table 125. GeoVax Recent Development Table 126. GenVec Company Information Table 127. GenVec Business Overview Table 128. GenVec Malaria Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 129. GenVec Malaria Vaccines Product Portfolio Table 130. GenVec Recent Development Table 131. Cipla Inc Company Information Table 132. Cipla Inc Business Overview Table 133. Cipla Inc Malaria Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 134. Cipla Inc Malaria Vaccines Product Portfolio Table 135. Cipla Inc Recent Development Table 136. CellFree Sciences Company Information Table 137. CellFree Sciences Business Overview Table 138. CellFree Sciences Malaria Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 139. CellFree Sciences Malaria Vaccines Product Portfolio Table 140. CellFree Sciences Recent Development Table 141. Bliss GVS Pharma Ltd Company Information Table 142. Bliss GVS Pharma Ltd Business Overview Table 143. Bliss GVS Pharma Ltd Malaria Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 144. Bliss GVS Pharma Ltd Malaria Vaccines Product Portfolio Table 145. Bliss GVS Pharma Ltd Recent Development Table 146. Amneal Pharmaceuticals LLC Company Information Table 147. Amneal Pharmaceuticals LLC Business Overview Table 148. Amneal Pharmaceuticals LLC Malaria Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 149. Amneal Pharmaceuticals LLC Malaria Vaccines Product Portfolio Table 150. Amneal Pharmaceuticals LLC Recent Development Table 151. AJANTA PHARMA Company Information Table 152. AJANTA PHARMA Business Overview Table 153. AJANTA PHARMA Malaria Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 154. AJANTA PHARMA Malaria Vaccines Product Portfolio Table 155. AJANTA PHARMA Recent Development Table 156. AdvaCare Pharma Company Information Table 157. AdvaCare Pharma Business Overview Table 158. AdvaCare Pharma Malaria Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 159. AdvaCare Pharma Malaria Vaccines Product Portfolio Table 160. AdvaCare Pharma Recent Development Table 161. Actiza Pharmaceutical Private Limited Company Information Table 162. Actiza Pharmaceutical Private Limited Business Overview Table 163. Actiza Pharmaceutical Private Limited Malaria Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 164. Actiza Pharmaceutical Private Limited Malaria Vaccines Product Portfolio Table 165. Actiza Pharmaceutical Private Limited Recent Development Table 166. North America Malaria Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 167. North America Malaria Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 168. North America Malaria Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 169. North America Malaria Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 170. North America Malaria Vaccines Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 171. North America Malaria Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 172. North America Malaria Vaccines Revenue by Country (US$ Million) & (2027-2032) Table 173. Europe Malaria Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 174. Europe Malaria Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 175. Europe Malaria Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 176. Europe Malaria Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 177. Europe Malaria Vaccines Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 178. Europe Malaria Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 179. Europe Malaria Vaccines Revenue by Country (US$ Million) & (2027-2032) Table 180. China Malaria Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 181. China Malaria Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 182. China Malaria Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 183. China Malaria Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 184. Asia Malaria Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 185. Asia Malaria Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 186. Asia Malaria Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 187. Asia Malaria Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 188. Asia Malaria Vaccines Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 189. Asia Malaria Vaccines Revenue by Region (US$ Million) & (2021-2026) Table 190. Asia Malaria Vaccines Revenue by Region (US$ Million) & (2027-2032) Table 191. SAMEA Malaria Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 192. SAMEA Malaria Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 193. SAMEA Malaria Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 194. SAMEA Malaria Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 195. SAMEA Malaria Vaccines Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 196. SAMEA Malaria Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 197. SAMEA Malaria Vaccines Revenue by Country (US$ Million) & (2027-2032) Table 198. Research Programs/Design for This Report Table 199. Authors List of This Report Table 200. Secondary Sources Table 201. Primary Sources List of Figures Figure 1. Malaria Vaccines Image Figure 2. Global Malaria Vaccines Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Malaria Vaccines Market Size Share 2021 VS 2025 VS 2032 Figure 4. Erythrocytic Vaccine Image Figure 5. Pre-Erythrocytic Vaccine Image Figure 6. Multi-antigen Vaccine Image Figure 7. Global Malaria Vaccines Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Malaria Vaccines Market Size Share 2021 VS 2025 VS 2032 Figure 9. Clinics Image Figure 10. Hospitals Image Figure 11. Community Centers Image Figure 12. Global Malaria Vaccines Market Size (US$ Million) & (2021-2032) Figure 13. Global Malaria Vaccines Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Malaria Vaccines Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Malaria Vaccines Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Malaria Vaccines Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Malaria Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Malaria Vaccines Revenue Market Share by Type (2021-2032) Figure 20. Global Malaria Vaccines Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Malaria Vaccines Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Malaria Vaccines Revenue Market Share by Application (2021-2032) Figure 23. North America Malaria Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Malaria Vaccines Revenue Share by Type (2021-2032) Figure 25. North America Malaria Vaccines Revenue Share by Application (2021-2032) Figure 26. North America Malaria Vaccines Revenue Share by Country (2021-2032) Figure 27. United States Malaria Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Malaria Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Malaria Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Malaria Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Malaria Vaccines Revenue Share by Type (2021-2032) Figure 32. Europe Malaria Vaccines Revenue Share by Application (2021-2032) Figure 33. Europe Malaria Vaccines Revenue Share by Country (2021-2032) Figure 34. Germany Malaria Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Malaria Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Malaria Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Malaria Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Malaria Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Malaria Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Malaria Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Malaria Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Malaria Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Malaria Vaccines Revenue Share by Type (2021-2032) Figure 44. China Malaria Vaccines Revenue Share by Application (2021-2032) Figure 45. Asia Malaria Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Malaria Vaccines Revenue Share by Type (2021-2032) Figure 47. Asia Malaria Vaccines Revenue Share by Application (2021-2032) Figure 48. Asia Malaria Vaccines Revenue Share by Region (2021-2032) Figure 49. Japan Malaria Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Malaria Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Malaria Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Malaria Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Malaria Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Malaria Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Malaria Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Malaria Vaccines Revenue Share by Type (2021-2032) Figure 57. SAMEA Malaria Vaccines Revenue Share by Application (2021-2032) Figure 58. SAMEA Malaria Vaccines Revenue Share by Country (2021-2032) Figure 59. Brazil Malaria Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Malaria Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Malaria Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Malaria Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Malaria Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Malaria Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Malaria Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Malaria Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Malaria Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Malaria Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Malaria Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Erythrocytic Vaccine
  • Pre-Erythrocytic Vaccine
  • Multi-antigen Vaccine
Applications
  • Clinics
  • Hospitals
  • Community Centers
Companies covered
  • Sanofi
  • Novartis AG
  • Mylan N.V.
  • Pfizer Inc
  • GlaxoSmithKline Plc
  • Zydus Cadila
  • VLP Therapeutics
  • Taj Pharmaceuticals Limited
  • Sun Pharmaceutical Industries Ltd
  • Sumaya Biotech
  • Strides Pharma Science Limited
  • Sanaria Inc
  • OSIVAX
  • Nobelpharma Co
  • Lupin
  • Ipca Laboratories Ltd
  • Hikma Pharmaceuticals PLC
  • GeoVax
  • GenVec
  • Cipla Inc
  • CellFree Sciences
  • Bliss GVS Pharma Ltd
  • Amneal Pharmaceuticals LLC
  • AJANTA PHARMA
  • AdvaCare Pharma
  • Actiza Pharmaceutical Private Limited

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Malaria Vaccines Market by Type
  3. 1.2.1 Global Malaria Vaccines Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Erythrocytic Vaccine
  5. 1.2.3 Pre-Erythrocytic Vaccine
  6. 1.2.4 Multi-antigen Vaccine
  7. 1.3 Malaria Vaccines Market by Application
  8. 1.3.1 Global Malaria Vaccines Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Clinics
  10. 1.3.3 Hospitals
  11. 1.3.4 Community Centers
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Malaria Vaccines Market Dynamics
  1. 2.1 Malaria Vaccines Industry Trends
  2. 2.2 Malaria Vaccines Industry Drivers
  3. 2.3 Malaria Vaccines Industry Opportunities and Challenges
  4. 2.4 Malaria Vaccines Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Malaria Vaccines Market Perspective (2021-2032)
  2. 3.2 Global Malaria Vaccines Growth Trends by Region
  3. 3.2.1 Global Malaria Vaccines Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Malaria Vaccines Market Size by Region (2021-2026)
  5. 3.2.3 Global Malaria Vaccines Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Malaria Vaccines Revenue by Players
  2. 4.1.1 Global Malaria Vaccines Revenue by Players (2021-2026)
  3. 4.1.2 Global Malaria Vaccines Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Malaria Vaccines Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Malaria Vaccines Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Malaria Vaccines Key Players Headquarters & Area Served
  7. 4.4 Global Malaria Vaccines Players, Product Type & Application
  8. 4.5 Global Malaria Vaccines Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Malaria Vaccines Market CR5 and HHI
  11. 4.6.3 2025 Malaria Vaccines Tier 1, Tier 2, and Tier 3
5 Malaria Vaccines Market Size by Type
  1. 5.1 Global Malaria Vaccines Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Malaria Vaccines Revenue by Type (2021-2032)
  3. 5.3 Global Malaria Vaccines Revenue Market Share by Type (2021-2032)
6 Malaria Vaccines Market Size by Application
  1. 6.1 Global Malaria Vaccines Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Malaria Vaccines Revenue by Application (2021-2032)
  3. 6.3 Global Malaria Vaccines Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sanofi
  2. 7.1.1 Sanofi Company Information
  3. 7.1.2 Sanofi Business Overview
  4. 7.1.3 Sanofi Malaria Vaccines Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi Malaria Vaccines Product Portfolio
  6. 7.1.5 Sanofi Recent Developments
  7. 7.2 Novartis AG
  8. 7.2.1 Novartis AG Company Information
  9. 7.2.2 Novartis AG Business Overview
  10. 7.2.3 Novartis AG Malaria Vaccines Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novartis AG Malaria Vaccines Product Portfolio
  12. 7.2.5 Novartis AG Recent Developments
  13. 7.3 Mylan N.V.
  14. 7.3.1 Mylan N.V. Company Information
  15. 7.3.2 Mylan N.V. Business Overview
  16. 7.3.3 Mylan N.V. Malaria Vaccines Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Mylan N.V. Malaria Vaccines Product Portfolio
  18. 7.3.5 Mylan N.V. Recent Developments
  19. 7.4 Pfizer Inc
  20. 7.4.1 Pfizer Inc Company Information
  21. 7.4.2 Pfizer Inc Business Overview
  22. 7.4.3 Pfizer Inc Malaria Vaccines Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Pfizer Inc Malaria Vaccines Product Portfolio
  24. 7.4.5 Pfizer Inc Recent Developments
  25. 7.5 GlaxoSmithKline Plc
  26. 7.5.1 GlaxoSmithKline Plc Company Information
  27. 7.5.2 GlaxoSmithKline Plc Business Overview
  28. 7.5.3 GlaxoSmithKline Plc Malaria Vaccines Revenue and Gross Margin (2021-2026)
  29. 7.5.4 GlaxoSmithKline Plc Malaria Vaccines Product Portfolio
  30. 7.5.5 GlaxoSmithKline Plc Recent Developments
  31. 7.6 Zydus Cadila
  32. 7.6.1 Zydus Cadila Company Information
  33. 7.6.2 Zydus Cadila Business Overview
  34. 7.6.3 Zydus Cadila Malaria Vaccines Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Zydus Cadila Malaria Vaccines Product Portfolio
  36. 7.6.5 Zydus Cadila Recent Developments
  37. 7.7 VLP Therapeutics
  38. 7.7.1 VLP Therapeutics Company Information
  39. 7.7.2 VLP Therapeutics Business Overview
  40. 7.7.3 VLP Therapeutics Malaria Vaccines Revenue and Gross Margin (2021-2026)
  41. 7.7.4 VLP Therapeutics Malaria Vaccines Product Portfolio
  42. 7.7.5 VLP Therapeutics Recent Developments
  43. 7.8 Taj Pharmaceuticals Limited
  44. 7.8.1 Taj Pharmaceuticals Limited Company Information
  45. 7.8.2 Taj Pharmaceuticals Limited Business Overview
  46. 7.8.3 Taj Pharmaceuticals Limited Malaria Vaccines Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Taj Pharmaceuticals Limited Malaria Vaccines Product Portfolio
  48. 7.8.5 Taj Pharmaceuticals Limited Recent Developments
  49. 7.9 Sun Pharmaceutical Industries Ltd
  50. 7.9.1 Sun Pharmaceutical Industries Ltd Company Information
  51. 7.9.2 Sun Pharmaceutical Industries Ltd Business Overview
  52. 7.9.3 Sun Pharmaceutical Industries Ltd Malaria Vaccines Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Sun Pharmaceutical Industries Ltd Malaria Vaccines Product Portfolio
  54. 7.9.5 Sun Pharmaceutical Industries Ltd Recent Developments
  55. 7.10 Sumaya Biotech
  56. 7.10.1 Sumaya Biotech Company Information
  57. 7.10.2 Sumaya Biotech Business Overview
  58. 7.10.3 Sumaya Biotech Malaria Vaccines Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Sumaya Biotech Malaria Vaccines Product Portfolio
  60. 7.10.5 Sumaya Biotech Recent Developments
  61. 7.11 Strides Pharma Science Limited
  62. 7.11.1 Strides Pharma Science Limited Company Information
  63. 7.11.2 Strides Pharma Science Limited Business Overview
  64. 7.11.3 Strides Pharma Science Limited Malaria Vaccines Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Strides Pharma Science Limited Malaria Vaccines Product Portfolio
  66. 7.11.5 Strides Pharma Science Limited Recent Developments
  67. 7.12 Sanaria Inc
  68. 7.12.1 Sanaria Inc Company Information
  69. 7.12.2 Sanaria Inc Business Overview
  70. 7.12.3 Sanaria Inc Malaria Vaccines Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Sanaria Inc Malaria Vaccines Product Portfolio
  72. 7.12.5 Sanaria Inc Recent Developments
  73. 7.13 OSIVAX
  74. 7.13.1 OSIVAX Company Information
  75. 7.13.2 OSIVAX Business Overview
  76. 7.13.3 OSIVAX Malaria Vaccines Revenue and Gross Margin (2021-2026)
  77. 7.13.4 OSIVAX Malaria Vaccines Product Portfolio
  78. 7.13.5 OSIVAX Recent Developments
  79. 7.14 Nobelpharma Co
  80. 7.14.1 Nobelpharma Co Company Information
  81. 7.14.2 Nobelpharma Co Business Overview
  82. 7.14.3 Nobelpharma Co Malaria Vaccines Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Nobelpharma Co Malaria Vaccines Product Portfolio
  84. 7.14.5 Nobelpharma Co Recent Developments
  85. 7.15 Lupin
  86. 7.15.1 Lupin Company Information
  87. 7.15.2 Lupin Business Overview
  88. 7.15.3 Lupin Malaria Vaccines Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Lupin Malaria Vaccines Product Portfolio
  90. 7.15.5 Lupin Recent Developments
  91. 7.16 Ipca Laboratories Ltd
  92. 7.16.1 Ipca Laboratories Ltd Company Information
  93. 7.16.2 Ipca Laboratories Ltd Business Overview
  94. 7.16.3 Ipca Laboratories Ltd Malaria Vaccines Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Ipca Laboratories Ltd Malaria Vaccines Product Portfolio
  96. 7.16.5 Ipca Laboratories Ltd Recent Developments
  97. 7.17 Hikma Pharmaceuticals PLC
  98. 7.17.1 Hikma Pharmaceuticals PLC Company Information
  99. 7.17.2 Hikma Pharmaceuticals PLC Business Overview
  100. 7.17.3 Hikma Pharmaceuticals PLC Malaria Vaccines Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Hikma Pharmaceuticals PLC Malaria Vaccines Product Portfolio
  102. 7.17.5 Hikma Pharmaceuticals PLC Recent Developments
  103. 7.18 GeoVax
  104. 7.18.1 GeoVax Company Information
  105. 7.18.2 GeoVax Business Overview
  106. 7.18.3 GeoVax Malaria Vaccines Revenue and Gross Margin (2021-2026)
  107. 7.18.4 GeoVax Malaria Vaccines Product Portfolio
  108. 7.18.5 GeoVax Recent Developments
  109. 7.19 GenVec
  110. 7.19.1 GenVec Company Information
  111. 7.19.2 GenVec Business Overview
  112. 7.19.3 GenVec Malaria Vaccines Revenue and Gross Margin (2021-2026)
  113. 7.19.4 GenVec Malaria Vaccines Product Portfolio
  114. 7.19.5 GenVec Recent Developments
  115. 7.20 Cipla Inc
  116. 7.20.1 Cipla Inc Company Information
  117. 7.20.2 Cipla Inc Business Overview
  118. 7.20.3 Cipla Inc Malaria Vaccines Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Cipla Inc Malaria Vaccines Product Portfolio
  120. 7.20.5 Cipla Inc Recent Developments
  121. 7.21 CellFree Sciences
  122. 7.21.1 CellFree Sciences Company Information
  123. 7.21.2 CellFree Sciences Business Overview
  124. 7.21.3 CellFree Sciences Malaria Vaccines Revenue and Gross Margin (2021-2026)
  125. 7.21.4 CellFree Sciences Malaria Vaccines Product Portfolio
  126. 7.21.5 CellFree Sciences Recent Developments
  127. 7.22 Bliss GVS Pharma Ltd
  128. 7.22.1 Bliss GVS Pharma Ltd Company Information
  129. 7.22.2 Bliss GVS Pharma Ltd Business Overview
  130. 7.22.3 Bliss GVS Pharma Ltd Malaria Vaccines Revenue and Gross Margin (2021-2026)
  131. 7.22.4 Bliss GVS Pharma Ltd Malaria Vaccines Product Portfolio
  132. 7.22.5 Bliss GVS Pharma Ltd Recent Developments
  133. 7.23 Amneal Pharmaceuticals LLC
  134. 7.23.1 Amneal Pharmaceuticals LLC Company Information
  135. 7.23.2 Amneal Pharmaceuticals LLC Business Overview
  136. 7.23.3 Amneal Pharmaceuticals LLC Malaria Vaccines Revenue and Gross Margin (2021-2026)
  137. 7.23.4 Amneal Pharmaceuticals LLC Malaria Vaccines Product Portfolio
  138. 7.23.5 Amneal Pharmaceuticals LLC Recent Developments
  139. 7.24 AJANTA PHARMA
  140. 7.24.1 AJANTA PHARMA Company Information
  141. 7.24.2 AJANTA PHARMA Business Overview
  142. 7.24.3 AJANTA PHARMA Malaria Vaccines Revenue and Gross Margin (2021-2026)
  143. 7.24.4 AJANTA PHARMA Malaria Vaccines Product Portfolio
  144. 7.24.5 AJANTA PHARMA Recent Developments
  145. 7.25 AdvaCare Pharma
  146. 7.25.1 AdvaCare Pharma Company Information
  147. 7.25.2 AdvaCare Pharma Business Overview
  148. 7.25.3 AdvaCare Pharma Malaria Vaccines Revenue and Gross Margin (2021-2026)
  149. 7.25.4 AdvaCare Pharma Malaria Vaccines Product Portfolio
  150. 7.25.5 AdvaCare Pharma Recent Developments
  151. 7.26 Actiza Pharmaceutical Private Limited
  152. 7.26.1 Actiza Pharmaceutical Private Limited Company Information
  153. 7.26.2 Actiza Pharmaceutical Private Limited Business Overview
  154. 7.26.3 Actiza Pharmaceutical Private Limited Malaria Vaccines Revenue and Gross Margin (2021-2026)
  155. 7.26.4 Actiza Pharmaceutical Private Limited Malaria Vaccines Product Portfolio
  156. 7.26.5 Actiza Pharmaceutical Private Limited Recent Developments
8 North America
  1. 8.1 North America Malaria Vaccines Revenue (2021-2032)
  2. 8.2 North America Malaria Vaccines Revenue by Type (2021-2032)
  3. 8.2.1 North America Malaria Vaccines Revenue by Type (2021-2026)
  4. 8.2.2 North America Malaria Vaccines Revenue by Type (2027-2032)
  5. 8.3 North America Malaria Vaccines Revenue Share by Type (2021-2032)
  6. 8.4 North America Malaria Vaccines Revenue by Application (2021-2032)
  7. 8.4.1 North America Malaria Vaccines Revenue by Application (2021-2026)
  8. 8.4.2 North America Malaria Vaccines Revenue by Application (2027-2032)
  9. 8.5 North America Malaria Vaccines Revenue Share by Application (2021-2032)
  10. 8.6 North America Malaria Vaccines Revenue by Country
  11. 8.6.1 North America Malaria Vaccines Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Malaria Vaccines Revenue by Country (2021-2026)
  13. 8.6.3 North America Malaria Vaccines Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Malaria Vaccines Revenue (2021-2032)
  2. 9.2 Europe Malaria Vaccines Revenue by Type (2021-2032)
  3. 9.2.1 Europe Malaria Vaccines Revenue by Type (2021-2026)
  4. 9.2.2 Europe Malaria Vaccines Revenue by Type (2027-2032)
  5. 9.3 Europe Malaria Vaccines Revenue Share by Type (2021-2032)
  6. 9.4 Europe Malaria Vaccines Revenue by Application (2021-2032)
  7. 9.4.1 Europe Malaria Vaccines Revenue by Application (2021-2026)
  8. 9.4.2 Europe Malaria Vaccines Revenue by Application (2027-2032)
  9. 9.5 Europe Malaria Vaccines Revenue Share by Application (2021-2032)
  10. 9.6 Europe Malaria Vaccines Revenue by Country
  11. 9.6.1 Europe Malaria Vaccines Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Malaria Vaccines Revenue by Country (2021-2026)
  13. 9.6.3 Europe Malaria Vaccines Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Malaria Vaccines Revenue (2021-2032)
  2. 10.2 China Malaria Vaccines Revenue by Type (2021-2032)
  3. 10.2.1 China Malaria Vaccines Revenue by Type (2021-2026)
  4. 10.2.2 China Malaria Vaccines Revenue by Type (2027-2032)
  5. 10.3 China Malaria Vaccines Revenue Share by Type (2021-2032)
  6. 10.4 China Malaria Vaccines Revenue by Application (2021-2032)
  7. 10.4.1 China Malaria Vaccines Revenue by Application (2021-2026)
  8. 10.4.2 China Malaria Vaccines Revenue by Application (2027-2032)
  9. 10.5 China Malaria Vaccines Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Malaria Vaccines Revenue (2021-2032)
  2. 11.2 Asia Malaria Vaccines Revenue by Type (2021-2032)
  3. 11.2.1 Asia Malaria Vaccines Revenue by Type (2021-2026)
  4. 11.2.2 Asia Malaria Vaccines Revenue by Type (2027-2032)
  5. 11.3 Asia Malaria Vaccines Revenue Share by Type (2021-2032)
  6. 11.4 Asia Malaria Vaccines Revenue by Application (2021-2032)
  7. 11.4.1 Asia Malaria Vaccines Revenue by Application (2021-2026)
  8. 11.4.2 Asia Malaria Vaccines Revenue by Application (2027-2032)
  9. 11.5 Asia Malaria Vaccines Revenue Share by Application (2021-2032)
  10. 11.6 Asia Malaria Vaccines Revenue by Country
  11. 11.6.1 Asia Malaria Vaccines Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Malaria Vaccines Revenue by Country (2021-2026)
  13. 11.6.3 Asia Malaria Vaccines Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Malaria Vaccines Revenue (2021-2032)
  2. 12.2 SAMEA Malaria Vaccines Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Malaria Vaccines Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Malaria Vaccines Revenue by Type (2027-2032)
  5. 12.3 SAMEA Malaria Vaccines Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Malaria Vaccines Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Malaria Vaccines Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Malaria Vaccines Revenue by Application (2027-2032)
  9. 12.5 SAMEA Malaria Vaccines Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Malaria Vaccines Revenue by Country
  11. 12.6.1 SAMEA Malaria Vaccines Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Malaria Vaccines Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Malaria Vaccines Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst